当前位置： SCI文献检索 > OncoTargets and Therapy期刊下所有文献 > Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.

Abstract：

Aim:The use of bevacizumab in combination therapy is an emerging trend in metastatic colorectal cancer treatment. However, the clinical value of different combination types remains under debate. Thus, a meta-analysis of randomized controlled trials (RCTs) comparing bevacizumab-based combination therapy with monotherapy (therapy that uses one type of treatment, such as chemotherapy or surgery alone, to treat metastatic colorectal cancer) was performed, aiming to evaluate the safety and efficacy of bevacizumab-based combination therapy and to find a more beneficial combination. Methods:We searched for clinical studies that evaluated bevacizumab-based combination therapy in metastatic colorectal cancer. We extracted data from these studies to evaluate the relative risk (RR) of overall response rate (ORR) and grade 3/4 treatment-related adverse events (AEs), HRs of overall survival (OS), and progression-free survival (PFS). Results:Eight RCTs were identified (n=3,424). Treatments included combinations of bevacizumab and oxaliplatin, fluorouracil, and leucovorin (FOLFOX4), combinations of bevacizumab and capecitabine and oxaliplatin, combinations of bevacizumab and fluorouracil/leucovorin, combinations of bevacizumab and irinotecan, fluorouracil, and leucovorin (IFL), and combinations of bevacizumab and capecitabine. Bevacizumab-based combination therapy showed higher ORR (RR: 1.40; 95% CI: 1.10-1.78; P=0.005), PFS (HR: 0.64; 95% CI: 0.55-0.73; P=0.000), and OS (HR: 0.82; 95% CI: 0.73-0.92; P=0.001) values than monotherapy. However, higher grade 3/4 treatment-related AEs (RR: 1.27; 95% CI: 1.15-1.41; P=0.000) were observed in combination therapy than in monotherapy. Conclusion:This meta-analysis showed that the addition of IFL to bevacizumab better benefits PFS and safety. Adding FOLFOX4 was associated with better ORR and OS. The efficacy and safety of an IFL-bevacizumab-FOLFOX4 combination should be given greater weight in future clinical trials, guidelines, and clinical practice.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Xu R,Xu C,Liu C,Cui C,Zhu J

doi

10.2147/OTT.S171724

subject

Has Abstract

pub_date

2018-12-04 00:00:00

pages

8605-8621

issn

1178-6930

pii

ott-11-8605

journal_volume

pub_type

杂志文章,评审

在线工具

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.